<?xml version="1.0" encoding="UTF-8"?>
<p>Potential candidates for the prevention and treatment of coronavirus infection are therefore peptides or small-molecular substances that block the membrane-associated enzyme ACE2, or alternatively inhibitors of TMPRSS2 (
 <xref ref-type="fig" rid="F1">figure</xref>). Camostat, an inhibitor of this protease, is licensed in Japan for treatment of chronic pancreatitis (
 <xref rid="R4" ref-type="bibr">4</xref>), but no clinical trials of camostat in coronavirus infection have yet been conducted. Among the clinical trials initiated to date, one project is investigating the administration of recombinant ACE2 enzyme to treat the infection (
 <xref rid="T1" ref-type="table">table 1</xref>). Soluble ACE2 might slow the spread by competitive binding to the virus. On the other hand, ACE2 antibodies might be a suitable means of blocking the virus’s access to the patient’s cells (
 <xref rid="R5" ref-type="bibr">5</xref>).
</p>
